Gesellschaft Deutscher Chemiker
Discovery of Bexobrutideg (NX-5948), an Oral Targeted Degrader of Bruton's Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies

Vortrag (Online-Veranstaltung)

Discovery of Bexobrutideg (NX-5948), an Oral Targeted Degrader of Bruton's Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies

Dr. Barbara Czako

Nurix Therapeutics

Discovery of Bexobrutideg (NX-5948), an Oral Targeted Degrader of Bruton's Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies
Veranstalter

FG Medizinische Chemie

Donnerstag, 25. September 2025

15:00 – 16:00
Registrierung

Tags

Interessen

Discovery of Bexobrutideg (NX-5948), an Oral Targeted Degrader of Bruton's Tyrosine Kinase (BTK) for the Treatment of B-cell Malignancies
Veranstalter

FG Medizinische Chemie

Donnerstag, 25. September 2025

15:00 – 16:00
Registrierung